Related references
Note: Only part of the references are listed.New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Optimisation of circulating biomarkers of cell death for routine clinical use
A. Greystoke et al.
ANNALS OF ONCOLOGY (2008)
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
A. Kalikaki et al.
BRITISH JOURNAL OF CANCER (2008)
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Daniel B. Costa et al.
CLINICAL CANCER RESEARCH (2008)
The Use of Genomics in Clinical Trial Design
Richard Simon
CLINICAL CANCER RESEARCH (2008)
Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: A perspective
Mary L. Bouxsein et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Estrogen- and progesterone-receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory
Sunil S. Badve et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A prototypical process for creating evidentiary standards for biomarkers and diagnostics
C. A. Altar et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
[Anonymous]
JOURNAL OF ONCOLOGY PRACTICE (2007)
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival
Daniel F. Hayes et al.
CLINICAL CANCER RESEARCH (2006)
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies
Paul Workman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Statistical evaluation of biomarkers as surrogate endpoints: a literature review
CJ Weir et al.
STATISTICS IN MEDICINE (2006)
The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis
Susan J. Cleator et al.
BREAST CANCER RESEARCH (2006)
Staged Risk Management of Candidate Drug Efficacy
Dominic Smethurst et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICAL MEDICINE (2005)
Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer
M Cristofanilli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Individual response to treatment: is it a valid assumption?
S Senn
BMJ-BRITISH MEDICAL JOURNAL (2004)
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
WJ Allard et al.
CLINICAL CANCER RESEARCH (2004)
How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development
P Workman
CURRENT PHARMACEUTICAL DESIGN (2003)
Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes
G Molenberghs et al.
STATISTICS IN MEDICINE (2001)
Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop
VG De Gruttola et al.
CONTROLLED CLINICAL TRIALS (2001)
Share Paper
